A Pre-Clinical Safety Evaluation of SBP (HBsAg-Binding Protein) Adjuvant for Hepatitis B Vaccine.
Although adjuvants are a common component of many vaccines, there are few adjuvants licensed for use in humans due to concerns about their toxic effects. There is a need to develop new and safe adjuvants, because some existing vaccines have low immunogenicity among certain patient groups. In this st...
Main Authors: | Jingbo Wang, Caixia Su, Rui Liu, Baoxiu Liu, Inam Ullah Khan, Jun Xie, Naishuo Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5245819?pdf=render |
Similar Items
-
A Study of Small Hepatitis B Surface Antigen (HBsAg) in the HBsAg Particle and HDV Formation
by: Chuan Jen Wang, et al.
Published: (2000) -
HBsAg in Cord Blood Qf Newborns of HBsAg-Positive Mothers
by: Adnan S. Wiharta, et al.
Published: (2018-11-01) -
Production of Recombinant HBsAg-Interleukin-2 Fusion Protein to Overcome MHC-Restricted Nonresponsiveness to HBsAg Vaccine
by: Guo, Shiu-Ping, et al.
Published: (1998) -
The study of HBsAg-specific memory cells in hepatitis B vaccinated population
by: Yu-Han Li, et al.
Published: (2007) -
LDH-isoenzymes and HBsAg.
by: Bharucha Z, et al.
Published: (1980-04-01)